Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  HUMAN VACCINES
A Global Strategic Business Report

This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The major product segments analyzed are Prophylactic Vaccines (Pediatric Prophylactic Vaccines, & Adult Prophylactic Vaccines), and Therapeutic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual forecasts are provided for each region for the period of 2001 through 2015. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 164 companies including many key and niche players worldwide such as ALK – Abelló A/S, Acambis PLC, Bavarian Nordic A/S, Crucell N.V., CSL Ltd., GlaxoSmithKline PLC, GlaxoSmithKline Biologicals S.A, Medimmune, Inc, Merck & Company, Inc., Novartis Vaccines & Diagnostics, Inc., Sanofi-Aventis S A, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics Ltd., Vaxin, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1176  PAGES:    778
PRICE:    $3950  DATE:       May 2008
COMPANIES:  164  MARKET DATA TABLES:   275
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  HUMAN VACCINES (Complete Report) Pages : 778   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations...I-1  
   Disclaimers...I-2
Data Interpretation & Reporting Level...I-2
  
   Quantitative Techniques & Analytics...I-3
Product Definitions and Scope of Study...I-3
Prophylactic Vaccines...I-3
Therapeutic Vaccines...I-3
  
II. EXECUTIVE SUMMARY142$2250
  1. Market Overview & Outlook...II-15 $500  
   Market Dynamics...II-11$100
   Global Human Vaccine Market: A Snapshot...II-2
Vaccine Pricing: The Developed – Developing Divide...II-2
Overview in the Recent Context...II-2
1$100
   Historical Perspective...II-3
Successful Vaccine Introductions in the Past...II-3
Looking Ahead...II-3
1$100
   Key Markets...II-4
Competitive Scenario...II-4
World’s Leading Producers...II-4
1$100
   Table 1: Leading Players in the Worldwide Human Vaccines Market (2005): Percentage Breakdown by Value Sales for Sanofi-Aventis, GlaxoSmithKline, Wyeth, Merck, and Others (includes corresponding Graph/Chart)...II-5
ALK- The Global Leader in Allergy Vaccines...II-5
Table 2: Leading Players in the Worldwide Allergy Vaccines Market (2005 & 2006): Percentage Breakdown by Value Sales for ALK-Abelló, Stallergenes, Allergopharma, and Others (includes corresponding Graph/Chart)...II-5
1$300
  2. Product Overview...II-645 $1600  
   Introduction to the Concept of Immunity...II-6
Role of Vaccines in Strengthening the Immune System...II-6
1$100
   Vaccines and Immunotherapy...II-7
Historical Overview of Vaccines...II-7
How it Began...II-7
1$100
   So Far So Good...II-8
Contribution of Animal Research to Vaccine Production...II-8
1$100
   Types of Vaccines...II-91$100
   Live, Attenuated Vaccines...II-101$100
   Combination Vaccines...II-11
Killed or Inactivated Vaccines...II-11
DNA & Recombinant DNA Vaccines...II-11
1$100
   Toxoids...II-12
Cellular Fractions...II-12
Conjugate Vaccines...II-12
1$100
   Subunit Vaccines...II-13
Passive Immunization...II-13
Prophylactic Vaccines...II-13
Prevention Better than Cure...II-13
Prophylactic Pediatric Vaccines...II-13
1$100
   Vaccination Over the Years...II-14
A Mature Market...II-14
1$100
   Challenges for Pediatric Vaccines Market...II-15
BCG Vaccine...II-15
1$100
   Growth Boosting Factors for TB Vaccines...II-16
Demand Restraining Factors for TB Vaccines...II-16
Major Issues to be addressed in the TB Vaccine Market...II-16
1$100
   Table 3: TB Vaccines Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-17
Hemophilus Influenza Type B Vaccine...II-17
Hib and Combination Vaccines by Producer...II-17
1$300
   Table 4: Pediatric Haemophilis Influenza B Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-18

Table 5: Pediatric Haemophilis Influenza B Vaccine Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)...II-18
Diphtheria/Tetanus/Pertussis Vaccines...II-18
1$300
   DTP, DTaP, and Combination Vaccines Offered by Major Producers in US...II-19
Table 6: Leading Players in the US DTP and DTaP Vaccines Market (2003-2005): Percentage Breakdown by Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmithkline, and Others (includes corresponding Graph/Chart)...II-19
1$300
   Table 7: DTP and DTaP Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-20

Table 8: DTP Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-20
Hepatitis A Vaccine...II-20
Hepatitis B Vaccine...II-20
1$300
   Hepatitis B Epidemiology...II-21
Table 9: Hepatitis B Vaccines Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-21
Measles/Mumps/Rubella Vaccines...II-21
1$300
   Table 10: Measles-Mumps-Rubella (MMR) Vaccine in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-22

Table 11: Measles-Mumps-Rubella (MMR) Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)...II-22
1$300
   Rotavirus Vaccines...II-23
Polio Vaccines...II-23
Table 12: Polio Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-23
1$300
   Table 13: Polio Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-24

Table 14: Polio Vaccine Market for Both Vaccine Types in the US: Annual Sales for 2000-2005 (In Million Doses) (includes correspondingGraph/Chart)...II-24

Table 15: Polio Vaccine Market for Both Vaccine Types (OPV and IPV) in the US in Percent of Doses from 2000-2005 (includes corresponding Graph/Chart)...II-24
1$300
   Varicella Vaccine...II-25
Table 16: Varicella Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-25
1$300
   Table 17: Varicella Vaccines Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart)...II-26
Need for Combination Vaccines...II-26
1$300
   Prophylactic Adult Vaccines...II-27
Favorable Market Growth...II-27
Hepatitis A Vaccine...II-27
1$100
   Hepatitis B Vaccines...II-281$100
   Key Issues Affecting the Adult Hepatitis Vaccines Market...II-29
Cholera Vaccine...II-29
Hepatitis A/Hepatitis B Vaccine...II-29
1$100
   Japanese Encephalitis Vaccines...II-30
Influenza Vaccines...II-30
1$100
   Table 18: Global Flu Vaccines Market (2005): Percentage Breakdown by Value Sales for the US, EU, and Rest of the World (includes corresponding Graph/Chart)...II-31

Table 19: Global Flu Vaccines Market (2005): Percentage Breakdown by Volume Sales for Sanofi Pasteur, Chiron, GSK and Others (includes corresponding Graph/Chart)...II-31

Table 20: Rate of Influenza Vaccine Consumption Among Target Groups (includes corresponding Graph/Chart)...II-31
1$300
   Table 21: Adult Influenza Vaccines Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-32
Growth Boosting Factors for Influenza Vaccines Market...II-32
Key Issues Affecting Influenza Vaccines Market...II-32
Age-Driven Strategies Drive Target Market for Influenza Vaccines...II-32
1$300
   Healthcare Professionals Increase Target Market for Influenza Vaccines...II-33
Lyme Disease Vaccine...II-33
Pneumococcal Disease Vaccines...II-33
1$100
   Meningococcal Vaccines...II-34
Rabies Vaccines...II-34
1$100
   Table 22: Rabies Vaccine Market Worldwide: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart)...II-35
Typhoid Vaccine...II-35
Yellow Fever Vaccine...II-35
Need for Additional Vaccines...II-35
2$450
   Therapeutic Vaccines...II-37
DNA Holds the Key...II-37
1$100
   Huge Potential for Protein Based Vaccines...II-38
Cancer Vaccines...II-38
Human Papillomavirus (HPV) Vaccine...II-38
Breakthroughs in Cancer Vaccine Market...II-38
1$100
   Factors Affecting the Market for Cancer Vaccines...II-39
Vaccine for AIDS...II-39
What is AIDS?...II-39
Global Statistics...II-39
1$100
   Table 23: Worldwide HIV/AIDS Estimates – 2007 (includes corresponding Graph/Chart)...II-40

Table 24: Worldwide HIV & AIDS Incidences (2007): A Regional Breakdown for Living and Newly Infected Cases (includes corresponding Graph/Chart)...II-40
1$300
   Table 25: Worldwide HIV & AIDS Prevalence Rate in Adults Aged between 15 and 49 Years for the Year 2007 (includes corresponding Graph/Chart)...II-41
Asia-Pacific...II-41
1$300
   Central Asia & Eastern Europe...II-42
Commonwealth of Independent States (CIS)...II-42
Latin America (Including the Caribbean Islands)...II-42
Sub Saharan Africa...II-42
1$100
   North Africa & the Middle East...II-43
Developed Regions and High Income Countries...II-43
United States...II-43
Table 26: New HIV Infection Cases among Men in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)...II-43
1$300
   Table 27: New HIV Infection Cases in the US (2006): Percentage Breakdown by Racial/Ethnic Groups (includes corresponding Graph/Chart)...II-44

Table 28: New HIV Infection Cases among Women in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart)...II-44
Development of Treatment Options...II-44
Categories of Vaccines for AIDS...II-44
1$300
   HIV Vaccines in Development...II-45
HIV Vaccines (Prophylactic/Therapeutic) Under Development (2007) by Key
  Manufacturers...II-45
Malaria Vaccine...II-45
1$100
   Therapeutic Vaccines Against Infectious Diseases: The Challenges...II-46
Melanoma: Prospects for Treatment...II-46
Vaccines for Melanoma in Development...II-46
Autoimmune Diseases...II-46
How Do Autoimmune Diseases Occur...II-46
Types of Autoimmune Diseases...II-46
Need for Developing Autoimmune Therapeutic Vaccines...II-46
1$100
   Travel Vaccines: Opportunities...II-47
SARS – Need for Urgent Solutions...II-47
1$100
   Vaccinations Recommended for Travel to High-Risk Areas...II-48
Mechanisms for Vaccine Delivery...II-48
1$100
   Edible Vaccines...II-491$100
   Oral Vaccines...II-50
Tablet Based Vaccines...II-50
Mucosal Delivery...II-50
Transdermal Patch Delivery...II-50
1$100
  3. Market Trends & Issues...II-5110 $700  
   Newer Vaccines in Pipeline to Cheer Up Pharma Companies...II-51
Threat of Pandemic Rejuvenates Vaccine Market...II-51
Influenza Vaccines On a Growing Spree...II-51
Influenza Market Faces Several Challenges...II-51
1$100
   Economic Factors Hamper Optimal Vaccine Development and Delivery...II-52
Increasing Need for Vaccine Promotion in the Developing Regions...II-52
Changing Vaccine Needs...II-52
1$100
   DNA Vaccines: Engineering Growth...II-531$100
   AIDS Vaccine: Long Road Ahead...II-54
Noninjectable Vaccines: Gain Without Pain...II-54
1$100
   Need for a Human Vaccine for Leishmaniasis...II-55
Conjugate Vaccines: A Technological Innovation...II-55
Need For a New TB Vaccine...II-55
1$100
   Companies Involved in TB Vaccine Research...II-56
Religious Concerns Over Immunizing Young Girls...II-56
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine...II-56
DTaP Vaccines Approved for Booster Vaccination...II-56
Advances in Biotechnology Spearheading Vaccines’ Growth...II-56
1$100
   BioWarfare: Threat Perception and Preparedness...II-57
Overview of Potential Bio-Terrorist Agents...II-57
Smallpox (Variola Major)...II-57
1$100
   Anthrax (Bacillus Anthracis)...II-58
Plague (Yersinia Pestis)...II-58
Botulism (Clostridium Botulinum)...II-58
Tularemia (Francisella Tularensis)...II-58
Market Concerns...II-58
Safety Factor...II-58
1$100
   Development Delays...II-59
Storage Problems...II-59
Perfluorocarbons as Alternative to Overcome Storage Problems...II-59
Costs...II-59
1$100
   Standards for Vaccine Safety and Quality...II-60
1$100
  4. Distribution Channels...II-611 $100  
   Distribution Channels...II-61
1$100
  5. Technological Developments...II-625 $500  
   Applying Gene Therapy to Develop Therapeutic Solutions...II-62
Research and Trials of AIDS Vaccines...II-62
Ongoing R&D for AIDS Vaccines...II-62
International AIDS Vaccine Initiative (IAVI)...II-62
1$100
   Cancer...II-63
Cancer Type and Area Effected...II-63
Immunotherapies for Cancer...II-63
Drugs for Cancer...II-63
1$100
   Issues Effecting the Development of Commercially Viable Cancer Vaccines...II-64
Frequency of Vaccination...II-64
Growth Boosters in the Cancer Vaccines Market...II-64
1$100
   Cancer Vaccines Available...II-65
Select Cancer Vaccines in Trial Stage...II-65
1$100
   Other Vaccines for Cancer...II-66
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines...II-66
1$100
  6. Clinical Trials...II-6710 $700  
   AVANT’s Single-Dose Oral Ty800 Vaccine Meets Key Endpoints...II-67
Emergent BioSolutions’ Typhoid Vaccine Completes Final Phase II Clinical Trial...II-67
Antigenics Announces Positive Data on Phase-I Study of ACAM-FLU-ATM Vaccine...II-67
1$100
   Bavarian Nordic’s IMVAMUNE® Post-Exposure Vaccination Demonstrates Protection Against
  Fatal Poxvirus Infection...II-68
BSU Scientists to Commence Human West Nile Vaccine Development Project...II-68
Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza
  Vaccine...II-68
1$100
   Protherics Commences Phase 2 Angiotensin Vaccine Study...II-69
CSL Biotherapies Files BLA for Influenza Vaccine...II-69
Orchestra Therapeutics Abandons Development of HIV Vaccine...II-69
1$100
   AlphaVax Concludes Phase I Clinical Trial of Flu Vaccine...II-70
AVANT Presents Preclinical Data on Enteric Vaccine...II-70
Baxter Declares Results of Seasonal Flu Vaccine Candidate Trial...II-70
1$100
   IDM Pharma Announces Interim Data of Phase II Clinical Trials of Lung Cancer
  Vaccine...II-71
Novavax Announces Developments in Discovery Program...II-71
1$100
   Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups...II-72
Acambis Initiates Test of single-dose JE vaccine in India...II-72
AVAX Technologies Initiates Phase 3 Clinical Trial For M-Vax...II-72
LigoCyte Pharmaceuticals Begins Clinical Testing of Norovirus Vaccine...II-72
1$100
   Alphavax Initiates Clinical Testing for Flu and CMV Vaccines...II-73
Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine...II-73
1$100
   Antigenics Reveals the Preliminary Data of Clinical Trial of Oncophage®...II-74
Baxter Reveals Phase I/II Clinical Trial Results of H5N1 Pandemic Vaccine...II-74
Crucell and AERAS Initiates Tuberculosis Vaccine Clinical Trial...II-74
DOR BioPharma Announces Phase I Results of RiVax™...II-74
GlaxoSmithKline Starts Clinical Trials to Test H5N1 Pandemic Flu Vaccines...II-74
1$100
   MedImmune Initiates Phase I Clinical Trial of Avian H5N1 Vaccine...II-75
MedImmune Reveals Results of Phase 3 Study for CAIV-T...II-75
MedImmune Initiates Second Phase 1 Study with MEDI-534...II-75
Sanofi Pasteur Initiates First Clinical Trial of Cell Based H7N1 Vaccine...II-75
Therion Biologics Completes Enrollment for Phase III trials of PANVAC-VF...II-75
1$100
   ViRexx Finishes the Treatment in Phase I Study of HepaVaxx B Vaccine...II-76
Antigenics Begins Phase I Clinical Trial of AG-707...II-76
Positive Results in Novavax’s Pandemic Influenza Vaccine Pre-clinical Trials...II-76
Trials Reveal H5N1 Pre-Pandemic Vaccine of Sanofi Pasteur Effective...II-76
PowderMed Reveals Reveals for Phase 1 Trials for Influenza Vaccine...II-76
Phase II clinical trials of China's hepatitis B vaccine...II-76
1$100
  7. Research Breakthroughs...II-772 $200  
   Findings Prove New Nose-Spray Vaccines Effective...II-77
Large Doses of H5N1 Influenza Vaccine Appears Effective...II-77
New Vaccine Technology to Prevent TB...II-77
HPV Vaccine to Help Prevent Cervical Cancer...II-77
Scientists Develop H7N1 Avian Influenza Vaccine...II-77
1$100
   Human H5N1 Vaccine Developed by Central Hygiene and Epidemiology Institute...II-78
1$100
  8. Product Development...II-791 $100  
   Nabi Biopharmaceuticals to Develop NicVax Vaccine for Reducing Nicotine
  Effects...II-79
GenPhar Develops Highly Effective Tetravalent Dengue Vaccine...II-79
Iomai Commences the Development of Prophylactic Traveler™s Diarrhea Vaccine...II-79
Biological Immunological to Produce and Sell r-Hepatitis B Vaccine...II-79
Thailand Researchers Commence the Development of Human Bird Flu Vaccine...II-79
USV to Commercialize Typhoid Vaccine...II-79
1$100
  9. Product Launches...II-803 $300  
   GlaxoSmithKline to Introduce Five Key Medicines for Oncology...II-80
FFF Enterprises Unveils My Flu Vaccine Network...II-80
ALK-Abelló Introduces GRAZAX® Anti-Allergy Vaccine...II-80
1$100
   Novartis Unveils Influenza Virus Vaccine Fluvirin®...II-81
Wyeth Introduces Latest 7-in-1 Pneumococcal Conjugate Vaccine...II-81
Intervet Releases Arnhem, a Prototype of Avian Influenza Vaccine...II-81
Shantha Launches ‘Jencevac’ Brain Fever Vaccine...II-81
Wockhardt and Zhejiang Introduces New Hepatitis-A Vaccine...II-81
1$100
   GSK Introduces Rotarix(R) Vaccines for Infants...II-82
Sinovac Biotech Introduces Bilive™...II-82
1$100
  10. Recent Industry Activity...II-8333 $1300  
   Emergent BioSolutions Acquires Group of Anthrax Monoclonal Antibodies from
  AVANIR...II-83
China Biopharma and BKXPC Enter into Agreement...II-83
Encorium Signs Contract with Protherics for Phase 2 Trial of ATV for
  Hypertension...II-83
1$100
   GenPhar to Establish Vaccine Production Plant in South Carolina...II-84
Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine...II-84
Intercell and PATH Malaria Vaccine Initiative Form New Partnership for Malaria
  Vaccine...II-84
Intercell Receives Manufacturer's License for Production of JE Vaccine...II-84
1$100
   GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine...II-85
Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial...II-85
1$100
   Pharmexa and Ichor Enter into Co-Development Agreement for Multiple DNA
  Vaccines...II-86
Crucell Enters into Exclusive Development Agreement with Wyeth Pharmaceuticals...II-86
Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals...II-86
1$100
   FDA Confers Priority Designation for Supplemental Application for GARDASIL ®...II-87
Sanofi Submits a European Marketing Approval Application for First Influenza
  Vaccine...II-87
1$100
   IVT Signs an MoU to Take Over Immunotope...II-88
Oxford BioMedica Takes Over Oxxon Therapeutics...II-88
DND Issues RFP for acquisition of MVA-based smallpox vaccine...II-88
GlaxoSmithKline Acquires Reliant Pharmaceuticals...II-88
1$100
   GSK Acquires Praecis Pharmaceuticals...II-89
Berna Biotech Divests Stake in Pevion Biotech...II-89
GeoVax Signs a Private Placement Agreement with Pure Capital...II-89
Crucell Inks a Research License Agreement with ISU ABXIS of Korea...II-89
China Biopharma Concludes Capital Funding to ZT Biotech...II-89
1$100
   Crucell and Acambis Ink a Licensing Agreement for PER. C6 ® Technology...II-90
Novartis and Intercell Join Hands to Advance Vaccine Programs...II-90
Serum Institute and Akorn Ink MoU for Vaccine Commercialization in US Market...II-90
1$100
   Merck Plans to Establish a Human Vaccine Facility in Ireland...II-91
Schering-Plough Acquires Organon Bio Sciences...II-91
Intas Biopharmaceuticals Enters into Collaboration Agreement with Virionics...II-91
Oxxon Therapeutics Starts U.S. Operation...II-91
1$100
   GenPhar and ImmuneRegen Enter into Research Partnership...II-92
Intercell Submits BLA for JE Vaccine to US FDA...II-92
AVANT and Select Vaccines Enter into R&D Partnership...II-92
1$100
   AVAX Enters into Agreement with Cancer Treatment Centers of America...II-93
CSC’s DVC and Baxter Receive Contract Modification from U.S. HHS...II-93
1$100
   DOR BioPharma Enters into CRADA with Walter Reed Army Institute...II-94
Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine...II-94
Emergent BioSolutions Commences Delivery of BioThrax® to US Health Department...II-94
1$100
   Maxygen and Sanofi Pasteur sign License Agreement...II-95
Beijing Public Health Bureau Enters into Purchase Agreement with Sinovac...II-95
Novartis Wins US Government Contract for Developing Antigen Technology...II-95
1$100
   MedImmune Announces Licensing of Reverse Genetics Technology to
  GlaxoSmithKline...II-96
MedImmune Wins US Government Contract...II-96
1$100
   MedImmune and Human Genome Sciences Sign Lease Agreement...II-97
Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur...II-97
Acambis Announces JE Partnership Agreement with Sanofi Pasteur...II-97
1$100
   Crucell Procures Major Patent for Influenza Vaccine Production...II-98
CSL Receives FDA Approval for Influenza Virus Vaccine...II-98
GlaxoSmithKline Inks Contract with UK Government...II-98
1$100
   Merck & Co., Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine...II-99
Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine
  Unit...II-99
Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit...II-99
1$100
   Amgen Acquires Abgenix...II-100
Pfizer Acquires PowderMed...II-100
CancerVax and Micromet Merge to Establish Micromet, Inc....II-100
Novartis Acquires Chiron...II-100
Dynavax Takes Over Rhein Biotech...II-100
1$100
   AnGes and Vical Ink Collaborative Agreement...II-101
GeoVax Merges with Dauphin...II-101
Hawaii Biotech and Avantogen Merge to Form New Entity...II-101
CytoDyn Acquires Advanced Influenza Technologies...II-101
Emergent BioSolutions Acquires VIVACS...II-101
Acambis Divests Berna Business to Crucell...II-101
Novavax Inks an Agreement with Bharat Biotech to Develop Avian Flu Vaccine...II-101
1$100
   Aeras Receives License for Developing and Distributing Tuberculosis Vaccine...II-102
Acambis to Supply Smallpox Vaccine to CDCP...II-102
AlphaVax and Wyeth Enhance Existing Licensing Agreement...II-102
Baxter Enters into a Contract to Supply Pandemic Influenza Vaccine...II-102
Sanofi Pasteur Signs Stockpile Contract with the US Government...II-102
1$100
   Crucell Licenses PER.C6® Technology to ADImmune Corporation...II-103
Baxter Wins Stockpile Production Contract for H5N1 from the NHS...II-103
Crucell Earns NIH Contract to Develop HIV Vaccine...II-103
Novartis Secures Stockpile Supply Contract from the US Government...II-103
Novartis Signs Distribution Agreement with Intercell...II-103
1$100
   GSK Receives Stockpile Supply Contract for Fly Pandemic from the HHS...II-104
GSK Signs H5N1 Antigen Influenza Vaccine Contract with Switzerland...II-104
DOR BioPharma Forms Alliance to Develop Ricin Vaccine...II-104
1$100
   Nobilon and NVI to Jointly Develop RSV Vaccine...II-105
SciGen and OctoPlus Join Forces to Develop Hepatitis B Vaccine Delivery...II-105
AlphaVax Receives Patent for Alphavaccines Manufacturing Process...II-105
IVI Receives Funds for Cholera Vaccine Development Program...II-105
Novavax Forms Strategic Alliance with US-based, PacificGMP...II-105
1$100
   Sanofi Pasteur Enters into Partnership with PDVI...II-106
MedImmune Inks a Cooperative R&D Agreement with NIAID...II-106
MedImmune Bags a Five-Year HHS Contract...II-106
Novavax Enters into a Cooperative Research Agreement with CDC...II-106
1$100
   GlaxoSmithKline Establishes New Vaccine Manufacturing Facility...II-107
GenPhar Extends R&D Contract with NMRC...II-107
Medlmmune Files for INDA with FDA for a New Influenza Vaccine...II-107
Rotarix™ Vaccines Receives European Approval...II-107
1$100
   Merck’s GARDASIL® Receives FDA Approval...II-108
CDC Adds Merck’s GARDASIL® Under its VFC Category in the US...II-108
Medlmmune Submits sBLA to the FDA Refrigerator-Stable Influenza Vaccine...II-108
Medlmmune Submits sBLA to the FDA for Expanded Label for CAIV-T...II-108
Medlmmune Receives FDA Approval for the Use of Reverse Genetics Technology...II-108
Vivalis Starts a New Plant in France to Produce Viral Vaccines...II-108
1$100
   Fiocruz Provides Yellow-Fever Vaccine to Peruvian Government...II-109
Merck Receives FDA Approval for Zostavax Vaccine...II-109
The US Health and Human Services Department Awards Grant to Pharma Companies...II-109
GlaxoSmithKline Expands License and Supply Agreement with Antigenics...II-109
GlaxoSmithKline Applies for Approval for Cervical Cancer Vaccine...II-109
Omnia Biologics Signs Deal with Aeras Global TB Vaccine Foundation...II-109
1$100
   Aeras Alliances with Dutch Scientific Organizations to Develop Latest TB
  Vaccines...II-110
Embrex, Shenzhen, and P.R. China Team Up for Manufacturing Influenza Vaccine...II-110
Health Canada Grants Approval to Merck’s RotaTeq...II-110
HepaLife Technologies Receives License for Technology from MSU...II-110
Hindustan Latex Ties-up with Bharat Biotech for Marketing Vaccines...II-110
Emergent BioSolutions and Sanofi Pasteur Sign Agreement...II-110
1$100
   USV and BCIL Enter into Agreement...II-111
GenVec Receives Fifth-Year Extension of Contract from NIAID...II-111
Inovio Joins Hands with Tripep to Develop Hepatitis C Vaccine...II-111
Novavax and Bharat Biotech Form Alliance to Develop Pandemic Flu Vaccine...II-111
1$100
   Panacea Biotech Joins Hands with NVI to Create Polio Vaccine...II-112
Immune Response Ties Up with Accelsiors for Trial of NeuroVax Vaccine...II-112
Nordic Vaccine Joins Forces with Ace BioSciences to Develop Efficient
  Vaccines...II-112
Eisai Partners with DNAVEC to Develop New Vaccine...II-112
ViRexx Partners with DRDC to Develop Biodefence Vaccines...II-112
1$100
   Biovirx Teams Up with IDT to Reintroduce Vaccine for Infants...II-113
LG Life Sciences Enters into Agreement with Sinovac...II-113
MediGene Awards Licenses to Virionics for CVLP Vaccine Program...II-113
FluLaval Influenza Vaccine Receives FDA Approval...II-113
1$100
   Merck Applies for Approval to Market Gardasil in China...II-114
Bio-Bridge Establishes New Vaccine Facility in China...II-114
SIIL Established the First-ever Biotech SEZ in India...II-114
Aeras Foundation Establishes New Laboratory for TB Vaccine...II-114
China Biopharma Distributes Flu Vaccine in China...II-114
ViroPro Founds New Subsidiary for Developing Medicinal Vaccines...II-114
1$100
   Glaxosmithkline Acquires Corixa Corporation...II-115
GSK Acquires ID Biomedical...II-115
Pharmexa Acquires GemVax...II-115
1$100
  11. Focus on Select Global Players...II-1169 $600  
   ALK – Abelló A/S (Denmark)...II-116
Acambis PLC (UK)...II-116
Bavarian Nordic A/S (Denmark)...II-116
1$100
   Crucell N.V. (The Netherlands)...II-1171$100
   CSL Ltd. (Australia)...II-118
GlaxoSmithKline PLC (UK)...II-118
2$200
   GlaxoSmithKline Biologicals S.A (Belgium)...II-120
Medimmune, Inc. (USA)...II-120
Merck & Company, Inc. (USA)...II-120
1$100
   Novartis Vaccines & Diagnostics, Inc. (USA)...II-121
Sanofi-Aventis S A (France)...II-121
1$100
   Sanofi-Pasteur SA (France)...II-122
Sanofi Pasteur Inc. (USA)...II-122
1$100
   Shantha Biotechnics Ltd. (India)...II-123
Vaxin, Inc. (USA)...II-123
1$100
   Wyeth (USA)...II-124
1$100
  12. Global Market Perspective...II-125   
   Table 29: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1251$300
   Table 30: World Long-term Projections for Human Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-1261$300
   Table 31: World Historic Market Review for Human Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...II-1271$300
   Table 32: World 10-Year Perspective for Human Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-1281$300
   Table 33: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1291$300
   Table 34: World Long-term Projections for Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-1301$300
   Table 35: World 10-Year Perspective for Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-1311$300
   Table 36: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Product Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1321$300
   Table 37: World Long-term Projections for Prophylactic Vaccines by Product Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-133

Table 38: World 10-Year Perspective for Prophylactic Vaccines by Product Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2003, 2008 & 2012...II-133
1$300
   Table 39: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1341$300
   Table 40: World Long-term Projections for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-1351$300
   Table 41: World 10-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-1361$300
   Table 42: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1371$300
   Table 43: World Long-term Projections for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-1381$300
   Table 44: World 10-Year Perspective for Adult Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-1391$300
   Table 45: World, Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...II-1401$300
   Table 46: World Long-term Projections for Therapeutic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-1411$300
   Table 47: World 10-Year Perspective for Therapeutic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-1421$300
III. MARKET135$1950
  1. The United States...III-152 $1575  
   A. Market Analysis...III-1
Outlook...III-1
Current & Future Analysis...III-1
Market Constraints...III-1
1$75
   Supply Shortages...III-2
Pediatric Vaccines Market...III-2
Market Focus Shifting From Pediatric Vaccines...III-2
Growth Boosting Factors for US Pediatric Vaccines Market...III-2
1$75
   Demand Restraining factors for US Pediatric Vaccines Market...III-3
Table 48: Pediatric Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart)...III-3
1$150
   Table 49: US Pediatric Vaccine Market: Percent of Doses by Vaccine Type – 2000 through 2005 (includes corresponding Graph/Chart)...III-4
‘Bright’ Outlook for Therapeutic Vaccines...III-4
Select Cancer Vaccines in Pipeline in the US...III-4
1$150
   Market Share of Key Players in North America...III-5
Table 50: Leading Players in the North American Human Vaccines Market (2005): Percentage Breakdown by Value Sales for Merck, Sanofi-Aventis, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart)...III-5
The US Influenza Vaccine Market...III-5
Table 51: The US Seasonal Influenza Vaccine Market – Production and Distribution of Influenza Vaccine in Million Units (includes corresponding Graph/Chart)...III-5
1$150
   Table 52: Funds Forwarded by HHS for Influenza Vaccine Production (2005-2006) to Key Vaccine Manufacturers (In US Dollars) (includes corresponding Graph/Chart)...III-6
Influenza Vaccine Producers for the 2006-2007 Influenza Season...III-6
Problems Effecting Timely Supply of Influenza Vaccine...III-6
1$150
   Table 53: Influenza Vaccines Market in the US (2005): Percentage Breakdown of Value Sales for Sanofi Aventis, Chiron, GSK, and Medimmune (includes corresponding Graph/Chart)...III-7
Key Statistics...III-7
Table 54: Number of Children Under 5 Years of Age in the US (In Millions) (includes corresponding Graph/Chart)...III-7
1$150
   Vaccines and Intended User Group...III-8
Need for Immunization Schedule for Adults...III-8
1$75
   Federal Research and Grants...III-9
National Cancer Institute...III-9
National Institutes of Health (NIH)...III-9
NIH Scientists Showcase Potential West Nile Virus Vaccine...III-9
NIH Doles Out Grants to Biotech Companies...III-9
1$75
   Development Funds for HIV Vaccines...III-10
Development Funds for Biodefense-Related Vaccines...III-10
The National Institute of Allergy and Infectious Diseases (NIAID)...III-10
Intramural Research...III-10
Extramural Divisions...III-10
1$75
   Vaccine Pricing in the US...III-11
Table 55: The US Vaccine Market: Vaccine Prices in US$ Per Dose (2002-2005) (includes corresponding Graph/Chart)...III-11
Regulatory Environment...III-11
Review Process Make Vaccines Safer...III-11
1$150
   Imports-Exports Scenario in the Recent Past...III-12
Exports of Human Vaccines for 2004...III-12
Table 56: US Domestic Exports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart)...III-12
Imports of Human Vaccines for 2004...III-12
Table 57: US Imports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart)...III-12
1$150
   Clinical Trials...III-137$525
   Product Developments...III-201$75
   Strategic Corporate Developments...III-2118$750
   Select Players...III-39
Alphavax Inc....III-39
Antigenics Inc....III-39
Avax Technologies, Inc....III-39
1$75
   Avant Immunotherapeutics, Inc....III-401$75
   Baxter International Inc....III-41
Cell Genesys Inc....III-41
1$75
   Dendreon Corporation...III-42
DOR Biopharma Inc....III-42
1$75
   Dynavax Technologies Corp....III-43
Emergent BioSolutions Inc....III-43
1$75
   GenPhar, Inc....III-44
IDM Pharma, Inc...III-44
1$75
   ImClone Systems, Inc....III-45
Ligocyte Pharmaceuticals, Inc...III-45
Maxygen, Inc....III-45
1$75
   MedImmune, Inc...III-46
Merck & Company, Inc...III-46
1$75
   Micromet, Inc....III-47
Novartis Vaccines & Diagnostics, Inc....III-47
Novavax, Inc....III-47
1$75
   Orchestra Therapeutics, Inc....III-48
Progenics Pharmaceuticals Inc. ....III-48
1$75
   Sanofi Pasteur Inc....III-49
Vaxin, Inc....III-49
1$75
   Wyeth...III-501$75
   B. Market Analytics...III-51
Table 58: US Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-51

Table 59: US Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-51
1$150
   Table 60: US Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-52

Table 61: US 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-52
1$150
  2. Canada...III-535 $425  
   A. Market Analysis...III-53
Clinical Trial...III-53
Strategic Corporate Developments...III-53
2$150
   B. Market Analytics...III-55
Table 62: Canadian Recent Past, Current & Future Analysis for Human Vaccines by Product Group / Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-55
1$150
   Table 63: Canadian Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-56

Table 64: Canadian Historic Review for Human Vaccines - Annual Sales Figures in US$$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-56
1$150
   Table 65: Canadian 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-57
1$150
  3. Japan...III-584 $375  
   A. Market Analysis...III-58
Strategic Corporate Development...III-58
1$75
   B. Market Analytics...III-59
Table 66: Japanese Recent Past, Current & Future Analysis for Human Vaccines by Product Group/ Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-59
1$150
   Table 67: Japanese Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-60

Table 68: Japanese Historic Review for Human Vaccines - Annual Sales Figures in US$$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-60
1$150
   Table 69: Japanese 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-61
1$150
  4. Europe...III-6210 $975  
   A. Market Analysis...III-62
Vaccine Pricing in Europe...III-62
Major Drawbacks...III-62
Current & Future Analysis...III-62
Regulatory Mechanism for Vaccines in Europe...III-62
1$75
   Select Players...III-63
Table 70: Leading Players in the European Human Vaccines Market (2005): Percentage Breakdown by Value Sales for GlaxoSmithKline & Sanofi Pasteur, Wyeth, and Others (includes corresponding Graph/Chart)...III-63

Table 71: Influenza Vaccines Market in Europe (2005 & 2006): Percentage Breakdown of Value Sales for Sanofi Pasteur, GSK, Novartis Vaccines, and Others in US$ Million (includes corresponding Graph/Chart)...III-63
Strategic Corporate Developments...III-63
2$300
   B. Market Analytics...III-65
Table 72: European Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-65
1$150
   Table 73: European Long-term Projections for Human Vaccines by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-661$150
   Table 74: European Historic Review for Human Vaccines by Geographic Region – France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-671$150
   Table 75: European 10-Year Perspective for Human Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-681$150
   Table 76: European Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-691$150
   Table 77: European Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-701$150
   Table 78: European 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-71
1$150
  4a. France...III-726 $425  
   A. Market Analysis...III-72
Clinical Trials...III-72
Strategic Corporate Developments...III-72
1$75
   Select Players...III-73
Sanofi-Aventis...III-73
1$75
   Sanofi Pasteur SA...III-741$75
   B. Market Analytics...III-75
Table 79: French Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-75
1$150
   Table 80: French Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-76

Table 81: French Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-76
1$150
   Table 82: French 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-77
1$150
  4b. Germany...III-784 $375  
   A. Market Analysis...III-78
Merck KgaA – A Major Player...III-78
Product Launch...III-78
Strategic Corporate Development...III-78
1$75
   B. Market Analytics...III-79
Table 83: Germany Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-79
1$150
   Table 84: Germany Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-80

Table 85: German Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-80
1$150
   Table 86: German 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-81
1$150
  4c. Italy...III-823 $325  
   Market Analysis...III-82
Table 87: Italian Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-82
1$150
   Table 88: Italian Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-83

Table 89: Italian Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-83
1$150
   Table 90: Italian 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-84
1$150
  4d. The United Kingdom...III-858 $575  
   A. Market Analysis...III-85
The UK Vaccine Industry Group (UVIG)...III-85
Clinical Trial...III-85
Product Development...III-85
1$75
   Strategic Corporate Developments...III-861$75
   Select Players...III-87
Acambis PLC...III-87
BioVex...III-87
1$75
   GlaxoSmithkline PLC...III-881$75
   Oxford Biomedica PLC...III-891$75
   B. Market Analytics...III-90
Table 91: UK Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-90
1$150
   Table 92: UK Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-91

Table 93: UK Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-91
1$150
   Table 94: UK 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-92
1$150
  4e. Spain...III-933 $325  
   Market Analysis...III-93
Table 95: Spanish Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-93
1$150
   Table 96: Spanish Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-94

Table 97: Spanish Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-94
1$150
   Table 98: Spanish 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-95
1$150
  4f. Russia...III-963 $325  
   Market Analysis...III-96
Table 99: Russian Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-96
1$150
   Table 100: Russian Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-97

Table 101: Russian Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-97
1$150
   Table 102: Russian 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-98
1$150
  4g. Rest of Europe...III-9914 $850  
   A. Market Analysis...III-99
Pediatric Vaccines Generate High Sales...III-99
Clinical Trials...III-99
1$75
   Strategic Corporate Developments...III-1006$450
   Select Players...III-106
ALK – Abelló A/S (Denmark)...III-106
Bavarian Nordic A/S (Denmark)...III-106
1$75
   Crucell N.V. (The Netherlands)...III-1071$75
   GlaxoSmithKline Biologicals S.A (Belgium)...III-108
Innogenetics NV (Belgium)...III-108
Intercell AG (Austria)...III-108
1$75
   Pharmexa A/S (Denmark)...III-1091$75
   B. Market Analytics...III-110
Table 103: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-110
1$150
   Table 104: Rest of Europe Long-term Projections for Human Vaccines by Product Group/Segment – Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-111

Table 105: Rest of Europe Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-111
1$150
   Table 106: Rest of Europe 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-112
1$150
  5. Asia-Pacific...III-11316 $975  
   A. Market Analysis...III-113
Asian Vaccine Industry...III-113
Challenges...III-113
China...III-113
1$75
   State Drug Administration: Regulatory Authority in China...III-114
India...III-114
Development Pipeline...III-114
1$75
   Hepatitis B Vaccine in India...III-1151$75
   Hepatitis B Vaccines in India...III-116
Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine...III-116
Combination Vaccines...III-116
Indian Vaccine Market - Combination Vaccines Available in the Country...III-116
1$75
   Indian Vaccine Market – New Combination Vaccines Under Development by Major
  Companies...III-117
International Players Entering the Arena...III-117
Major Partnerships Between Indian and International Players...III-117
1$75
   Heading Towards Greener Pastures...III-118
The Patent Act (Third Amendment), 2005...III-118
Clinical Trials...III-118
1$75
   Product Developments...III-119
Strategic Corporate Developments...III-119
4$300
   Select Players...III-123
CSL Ltd. (Australia)...III-123
1$75
   GreenCross Vaccine Co., Ltd. (South Korea)...III-124
Human Biologicals Institute (India)...III-124
1$75
   Serum Institute of India, Ltd. (India)...III-125
Shantha Biotechnics Ltd. (India)...III-125
Sinovac Biotech Co. Ltd. (China)...III-125
Wockhardt Limited (India)...III-125
1$75
   B. Market Analytics...III-126
Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-126
1$150
   Table 108: Asia-Pacific Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-127

Table 109: Asia-Pacific Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-127
1$150
   Table 110: Asia-Pacific 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-128
1$150
  6. Latin America...III-1294 $375  
   A. Market Analysis...III-129
Need for an effective TB Vaccine in Brazil...III-129
Product Launch...III-129
Strategic Corporate Development...III-129
1$75
   B. Market Analytics...III-130
Table 111: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-130
1$150
   Table 112: Latin America Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-131

Table 113: Latin America Historic Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-131
1$150
   Table 114: Latin American 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-132
1$150
  7. Rest of World...III-1333 $450  
   Market Analysis...III-133
Table 115: Rest of World Recent Past, Current & Future Analysis for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)...III-133
1$150
   Table 116: Rest of World Long-term Projections for Human Vaccines by Product Group/Segment - Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-134

Table 117: Rest of World Review for Human Vaccines - Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes corresponding Graph/Chart)...III-134
1$150
   Table 118: Rest of World 10-Year Perspective for Human Vaccines by Product Group/Segment – Percentage Breakdown of Dollar Sales for Prophylactic Vaccines (Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines) and Therapeutic Vaccines Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-1351$150
IV. COMPETITIVE LANDSCAPE 476$995
  
Total Companies Profiled: 164 (including Division/Subsidiaries - 195)

Region/Country                 Players

The United States                 84
Canada                             5
Japan                              8
Europe                            54
     France                        8
     Germany                       5
     The United Kingdom            9
     Italy                         3
     Spain                         2
     Russia                        1
     Rest of Europe               26
Asia-Pacific (Excluding Japan)    41
Africa                             1
Latin America                      2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2009, Global Industry Analysts, Inc., USA.